Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05521282
Other study ID # QLDXP-202002
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 9, 2021
Est. completion date June 30, 2022

Study information

Verified date August 2022
Source Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Research purpose: This study was a multicenter, randomized, double-blind, placebo-controlled, post-marketing clinical study in Chinese patients with essential hypertension to evaluate the efficacy and safety of Qianglidingxuan tablets(QLT) in the treatment of blood pressure in patients with mild to moderate essential hypertension. 1. Subject: Patients diagnosed as essential hypertension with clinical grade 1-2. 2. Interventions: ①Basic treatment plan:Patients in both groups were required to have a low-salt, low-fat diet, quit smoking, limit alcohol, eat more vegetables, moderate exercise, control body weight, and amlodipine besylate tablets (5mg, QD). ②Treatment group: Based on the basic treatment, QLT was given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks. ③Control group: Based on basic treatment, QLT mimetic were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks. 3. Treatment and follow-up cycle: Patients in both groups were treated for 12 weeks and followed up to the end of 48th week after treatment. 4. Provisions of concurrent treatment: Any combined treatment used during the study should be recorded in the CRF, including drug name (generic name/trade name), starting time, administration dose, method of administration, termination time, indication, etc 5. Efficacy evaluation: ①Primary outcome measure: the change from baseline in office blood pressure after 12 weeks of treatment. ②Secondary efficacy indicators: 24-hour ambulatory blood pressure, heart rate, blood lipids, homocysteine, CRP, baPWV. TCM syndromes (including vertigo, headache, impatience and irritability, red face, red eyes, dry mouth, bitter mouth, tinnitus, insomnia, multiple dreams, constipation, urination, etc.) ③Safety indicators: adverse events, vital signs, physical examination, laboratory examination 6. Statistics: SAS® 9.4 was used for all statistical analyses.


Recruitment information / eligibility

Status Completed
Enrollment 269
Est. completion date June 30, 2022
Est. primary completion date June 3, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Men and women aged 18-75 years. 2. Patients diagnosed as essential hypertension with clinical grade 1-2. 3. Diagnosis of hyperactivity of liver Yang upper syndrome by TCM syndrome differentiation. 4. Patients signed the informed consent with good compliance and could cooperate with the follow-up and review. Exclusion Criteria: 1. Secondary hypertension: renal hypertension (renovascular hypertension, renal parenchymal hypertension), pheochromocytoma, primary aldosteronism, Cushing syndrome, abdominal aortic coarctation, etc. 2. Coronary atherosclerotic heart disease, acute attack of chronic heart failure, malignant arrhythmia, valvular heart disease, cardiomyopathy and other serious cardiovascular diseases. 3. Acute cerebrovascular diseases such as cerebral infarction and cerebral hemorrhage. 4. Severe psychological disorder, intellectual disability or language disorder, resulting in inability to fully cooperate with the study and inability to complete the study. 5. Any laboratory test index before screening met the following criteria: admission liver and kidney function indicated that ALT, AST > 1.5 times the upper limit of normal value, Cr > 1.2 times the upper limit of normal value (refer to the laboratory normal range of the research center); Other clinically significant laboratory abnormalities that were deemed unsuitable for enrollment by the investigator. 6. Allergic constitution or allergic to strong fixed glare tablets, excipients or similar ingredients of the trial drug. 7. Suspected or with a history of alcohol or drug abuse. 8. Pregnant, lactating women or those who plan to get pregnant recently or are unwilling to use contraceptive measures;. 9. Patients who had participated in other clinical trials within 3 months before enrollment. 10. Patients deemed by the investigator to be ineligible for enrollment in the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Treatment group
Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

Locations

Country Name City State
China Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing

Sponsors (5)

Lead Sponsor Collaborator
Guang'anmen Hospital of China Academy of Chinese Medical Sciences Jilin Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinic blood pressure Changes in systolic and diastolic blood pressure from baseline to follow up Baseline, month 4, month 12
Secondary 24-hour ambulatory blood pressure Changes in daytime systolic BP, daytime diastolic blood pressure, nighttime systolic blood pressure, nighttime diastolic blood pressure, 24h mean systolic blood pressure, and 24h mean diastolic blood pressure from baseline to follow up Baseline, month 4, month 12
Secondary Heart rate Changes in heart rate from baseline to follow up Baseline, month 4, month 12
Secondary Blood lipids Changes in blood lipids(triglyceride, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol)from baseline to follow up Baseline, month 4, month 12
Secondary BMI Changes in BMI from baseline to follow up Baseline, month 4, month 12
Secondary Homocysteine Changes in homocysteine from baseline to follow up Baseline, month 4, month 12
Secondary C reactive protein Changes in C reactive protein from baseline to follow up Baseline, month 4, month 12
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A